12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Potiga regulatory update

Germany's Federal Joint Committee (G-BA) granted a request from GlaxoSmithKline for a new benefit assessment of epilepsy drug Trobalt retigabine. GSK now has 3 months to submit a new dossier for the drug....

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >